Alena Reznik, MD
Ophthalmology · Newport Beach, CANPI 1871720987
Payments from drug & device makers
Across 291 payments — averaging $403.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$53K
- Glaukos Corporation$28K
- Aerie Pharmaceuticals, Inc.$24K
- Johnson & Johnson Surgical Vision, Inc.$4K
- Alcon Research LLC$3K
- Dompe Farmaceutici S.p.a.$2K
- plus $4K from 17 others
What the payments were for
- Consulting fees$44,11044%
- Speaking & faculty fees$43,73743%
- Travel & lodging$3,6854%
- Food & beverage$9,82510%
- Entertainment$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 113 | $52,707 |
| Glaukos Corporation | 49 | $27,808 |
| Aerie Pharmaceuticals, Inc. | 49 | $24,200 |
| Johnson & Johnson Surgical Vision, Inc. | 23 | $3,757 |
| Alcon Research LLC | 2 | $2,820 |
| Dompe Farmaceutici S.p.a. | 1 | $2,400 |
| Alcon | 14 | $1,402 |
| NEW World Medical,inc. | 8 | $536 |
| Sight Sciences, Inc. | 6 | $435 |
| Amgen | 4 | $297 |
| Ivantis, Inc | 2 | $181 |
| Oyster Point Pharma, Inc. | 2 | $139 |
| Tarsus Pharmaceuticals, Inc. | 1 | $120 |
| Thea Pharma Inc. | 5 | $118 |
| Apellis Pharmaceuticals, Inc. | 1 | $113 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $112 |
| Nova Eye, Inc. | 1 | $68 |
| Stryker | 1 | $52 |
| Bausch & Lomb Americas Inc. | 1 | $48 |
| Rxsight Inc | 1 | $29 |
| Optos, Inc. | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Beaver-visitec International, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$23,473
- Rhopressa$23,357
- DURYSTA$17,012
- iStent Trabecular Micro-Bypass Stent System$16,021
- iStent inject Trabecular Micro-Bypass Stent System$13,984
- LUMIGAN$6,770
- iStent inject W$3,565
- Hydrus Microstent$3,105
- Tecnis Simplicity$3,000
- COMBIGAN$2,745
- XEN$2,730
- Tecnis IOL$1,606
- OMNI(R) SURGICAL SYSTEM (US)$370
- iDoseTR$332
- iStent Infinite$164
- TEPEZZA$138
- ARGOS$126
- Hydrus$124
- XEN GLAUCOMA TREATMENT SYSTEM$124
- VUITY$123
How this compares
$117,399 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 189 | $72,579 |
| CombiganBrimonidine Tartrate/Timolol | 52 | $22,333 |
| Alphagan PBrimonidine Tartrate | 42 | $21,250 |
| RhopressaNetarsudil Mesylate | 25 | $14,344 |
| VyzultaLatanoprostene Bunod | 21 | $12,894 |
| Cyclosporine | 29 | $12,430 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 41 | $11,368 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $7,071 |
| Travoprost | 44 | $6,669 |
| Brimonidine Tartrate | 83 | $6,088 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 253 | $4,765 |
| ZioptanTafluprost/Pf | 14 | $4,077 |
| Prednisolone Acetate | 85 | $4,013 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 26 | $3,973 |
| TafluprostTafluprost/Pf | 22 | $3,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $52,707 | $116,162283 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $24,200 | $21,41541 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $48 | $12,89421 claims |
| AlconSimbrinza | $1,402 | $11,36841 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Newport Beach
- David WirtaNewport Beach$18.4M
- Sheri RowenNewport Beach$1.8M
- Ehsan SadriNewport Beach$1.3M
- Nisha AcharyaSan Francisco$33M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.